FDA approves intravenous form of Merck nausea drug

NEW YORK, Jan 29 (Reuters) - Merck & Co (MRK.N) said on Tuesday that U.S. health regulators approved a new intravenous form of its anti-nausea drug Emend for patients undergoing chemotherapy.

The Food and Drug Administration approved injectable Emend for use in combination with other anti-nausea medicines for the prevention of acute and delayed nausea and vomiting associated with chemotherapy, Merck said.

Emend was previously available in oral capsule form. (Reporting by Bill Berkrot)